Argenx Se: Strong Market Position and Growth Potential with Vyvgart Leading the Charge

Wedbush analyst David Nierengarten reiterated a Buy rating on Argenx Se (ARGX – Research Report) on February 27 and set a price target of $715.00.

David Nierengarten has given his Buy rating due to a combination of factors that highlight Argenx Se’s strong market position and growth potential. The company’s flagship product, Vyvgart, has shown impressive revenue growth, particularly in the CIDP and gMG markets, with a robust trajectory of patient adoption and expansion into earlier treatment lines. The lack of significant competition from other gMG agents further strengthens Vyvgart’s market position.
Additionally, upcoming regulatory approvals, such as the anticipated FDA approval of pre-filled syringes for Vyvgart Hytrulo, are expected to enhance dosing convenience and expand market penetration. Argenx’s ongoing development pipeline, including multiple registrational and proof-of-concept studies, suggests continued innovation and potential market expansion. The company’s transition towards profitability by 2025 also contributes to the optimistic outlook, supporting the Buy recommendation.

Nierengarten covers the Healthcare sector, focusing on stocks such as Oric Pharmaceuticals, AnaptysBio, and Chimerix. According to TipRanks, Nierengarten has an average return of 7.3% and a 40.86% success rate on recommended stocks.